Moleculin Biotech Overview
- Status
-
Public
- Employees
-
18
- Stock Symbol
-
MBRX
- Investments
-
2
- Share Price
-
$2.37
- (As of Monday Closing)
Moleculin Biotech General Information
Description
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Contact Information
Website
www.moleculin.comCorporate Office
- 5300 Memorial Drive
- Suite 950
- Houston, TX 77007
- United States
Corporate Office
- 5300 Memorial Drive
- Suite 950
- Houston, TX 77007
- United States
Moleculin Biotech Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.37 | $2.44 | $2.12 - $15.75 | $6.74M | 2.84M | 40K | -$11.81 |
Moleculin Biotech Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | (8,128) | 1,506 | (19,570) | (21,835) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (26,024) | (31,010) | (29,135) | (16,036) |
| Net Income | (25,167) | (29,769) | (29,025) | (15,894) |
| Total Assets | 25,575 | 38,217 | 57,422 | 84,090 |
| Total Debt | 532 | 574 | 451 | 159 |
Moleculin Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Moleculin Biotech Comparisons
Industry
Financing
Details
Moleculin Biotech Competitors (10)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bellicum Pharmaceuticals | Formerly VC-backed | Houston, TX | ||||
| Lexicon Pharmaceuticals | Corporation | The Woodlands, TX | ||||
| Incyte | Formerly VC-backed | Wilmington, DE | ||||
| Syndax | Formerly VC-backed | Waltham, MA | ||||
| Actinium Pharmaceuticals | Formerly VC-backed | New York, NY |
Moleculin Biotech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Moleculin Biotech Patents
Moleculin Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021239927-A1 | Method of treating viral infections with hexose type monosaccharides and analogs thereof | Pending | 16-Mar-2020 | ||
| JP-2023518249-A | Method for treating viral infections with hexose-type monosaccharides and analogues thereof | Pending | 16-Mar-2020 | ||
| EP-4121060-A1 | Method of treating viral infections with hexose type monosaccharides and analogs thereof | Pending | 16-Mar-2020 | ||
| CA-3170872-A1 | Method of treating viral infections with hexose type monosaccharides and analogs thereof | Pending | 16-Mar-2020 | ||
| US-20230130134-A1 | Method of treating viral infections with hexose type monosaccharides and analogs thereof | Pending | 16-Mar-2020 | A61K31/70 |
Moleculin Biotech Executive Team (10)
| Name | Title | Board Seat |
|---|---|---|
| Walter Klemp | Co-Founder, President, Chief Executive Officer & Chairman | |
| Jonathan Foster | Chief Financial Officer, Finance & Chief Accounting Officer, Accounting | |
| Donald Picker Ph.D | Chief Scientific Officer | |
| Waldemar Priebe Ph.D | Co-Founder, Founding Scientist and Chair of Scientific Advisory Board |
Moleculin Biotech Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Self | Board Member | ||
| Self | Board Member | ||
| Self | Board Member | ||
| Self | Board Member | ||
| Self | Board Member |
Moleculin Biotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Moleculin Biotech Investments & Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| AnnaMed | 21-Aug-2015 | Pharmaceuticals | |||
| IntertechBio (License Rights of WP1122 Portfolio) | 01-Jan-2015 | Corporate Asset Purchase | Buildings and Property |
Moleculin Biotech FAQs
-
Who is the founder of Moleculin Biotech?
Walter Klemp, Lori Bisson, and Waldemar Priebe Ph.D are the founders of Moleculin Biotech.
-
Who is the CEO of Moleculin Biotech?
Walter Klemp is the CEO of Moleculin Biotech.
-
Where is Moleculin Biotech headquartered?
Moleculin Biotech is headquartered in Houston, TX.
-
What is the size of Moleculin Biotech?
Moleculin Biotech has 18 total employees.
-
What industry is Moleculin Biotech in?
Moleculin Biotech’s primary industry is Pharmaceuticals.
-
Is Moleculin Biotech a private or public company?
Moleculin Biotech is a Public company.
-
What is Moleculin Biotech’s stock symbol?
The ticker symbol for Moleculin Biotech is MBRX.
-
What is the current stock price of Moleculin Biotech?
As of 14-Oct-2024 the stock price of Moleculin Biotech is $2.37.
-
What is the current market cap of Moleculin Biotech?
The current market capitalization of Moleculin Biotech is $6.74M.
-
Who are Moleculin Biotech’s competitors?
Bellicum Pharmaceuticals, Lexicon Pharmaceuticals, Incyte, Syndax, and Actinium Pharmaceuticals are some of the 10 competitors of Moleculin Biotech.
-
What is Moleculin Biotech’s annual earnings per share (EPS)?
Moleculin Biotech’s EPS for 12 months was -$11.81.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
